NVNO enVVeno Medical Corporation

$NVNO I would love to see retail voting against the proposed equity plan (1) Incredibly slow progress (on purpose until plan gets approved??). Not even one patient enrolled yet (management likely wants the equity plan approved first before pumping the stock...) (2) No insiders buying (why buy when you can get free cheap options) in sharp contrast to CEO presenting $NVNO as a generational investment opportunity. (3) >30% dilution from proposed equity plan. (4) New plan allows management to reprice the options as needed without a vote. <1% insiders ownership 14.8% institutional ownership 7.5% T Satterfield 77% general retail Good luck getting a positive vote

$NVNO Why is this scam still trading on the NASDAQ? Send to pink sheets. Paying CEO 1 million a year for a failed FDA product. Why are they paying a VP of marketing? All cash is just paying executives - the Tavve trial will fail too

$NVNO Burnt about 130-140 million to get to this point with nothing to show and a 5mil MC. Huge self-offering in the back and ATM waiting to be used on the smallest volume increase. Buy below 2 after the imminent dilution.

$NVNO will showcase its enVVe System at the 38th TCT symposium on Nov 2, highlighting a new treatment for deep venous disease.

$NVNO I hope they get voted down again (unless they announce any decent progress, like 1st patient being enrolled, by the time vote happens): "The Administrator may, without stockholder approval (i) amend an outstanding option or stock appreciation right to reduce the exercise price of the Award, (ii) cancel, exchange, or surrender an outstanding option or stock appreciation right in exchange for cash or other Awards for the purpose of repricing the Award, or (iii) cancel, exchange, or surrender an outstanding option or stock appreciation right in exchange for an option or stock appreciation right with an exercise price that is less than the exercise price of the original Award"